Neuland Vilanterol Trifenatate Neuland Vilanterol Trifenatate

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find Radio Compass News for Vilanterol

    Client Email Product

    Vilanterol

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    PRICE INFORMATION

    INTERMEDIATES

    DOSSIERs // Finished Dosage Formulations

    DRUG PRODUCT COMPOSITION

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS

    ANALYTICAL SOLUTION(s)

    DIGITAL CONTENT

    PharmaCompass
    Related ProductsRelated Products
    API SUPPLIERS
    API Suppliers

    API Suppliers

    26
    US DMFs Filed

    US DMFs Filed

    7
    CEP/COS Certifications

    CEP/COS Certifications

    0

    JDMFs Filed

    JDMFs Filed

    0

    Other Certificates

    Other Certificates

    4
    Other Suppliers

    Other Suppliers

    23
    API REF. PRICE (USD / KG)
    315,301

    API Market Place

    2
    INTERMEDIATES
    10
    DOSSIERS // FDF
    USA (Orange Book)

    USA (Orange Book)

    6
    Europe

    Europe

    12
    Canada

    Canada

    0

    Australia

    Australia

    0

    South Africa

    South Africa

    3
    Uploaded Dossiers

    Uploaded Dossiers

    0

    GLOBAL SALES (USD Million)

    U.S. Medicaid

    0

    Annual Reports

    0

    FDF Market Place

    0

    EXCIPIENTS
    35
    PATENTS & EXCLUSIVITIES

    USFDA Orange Book Patents

    110

    USFDA Exclusivities

    4
    DIGITAL CONTENT

    Blog #PharmaFlow

    1

    News

    41
    REF STANDARD

    EDQM

    0

    USP

    0

    JP

    0

    Other Listed Suppliers

    10
    SERVICES

    0

    left grey arrow
    right gray arrow
    • POWDER;INHALATION - EQ 0.0625MG BASE/INH;EQ 0.025MG BASE/INH
    • POWDER;INHALATION - 0.05MG/INH;EQ 0.025MG BASE/INH
    • POWDER;INHALATION - 0.1MG/INH;EQ 0.025MG BASE/INH
    • POWDER;INHALATION - 0.2MG/INH;EQ 0.025MG BASE/INH
    Full View ScreenFull Screen View
    GSK launches once daily, single inhaler-triple therapy for COPD patients
    GSK launches once daily, single inhaler-triple therapy for COPD patients

    https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/gsk-launches-once-daily-single-inhaler-triple-therapy-for-copd-patients/articleshow/91095214.cms

    ECONOMICTIMES
    26 Apr 2022
    Share Share
    CHMP opinions: EMA refuses asthma label expansion for GSK’s COPD Ellipta
    CHMP opinions: EMA refuses asthma label expansion for GSK’s COPD Ellipta

    https://www.pharmaceutical-technology.com/news/ema-gsk-trelegy-asthma-refusal/

    Allie Nawrat PHARMACEUTICAL-TECHNOLOGY
    01 Mar 2021
    Share Share
    FDA Approvals Roundup: Detectnet, Nityr, Trelegy Ellipta
    FDA Approvals Roundup: Detectnet, Nityr, Trelegy Ellipta

    https://www.raps.org/news-and-articles/news-articles/2020/9/fda-approvals-roundup-detectnet-trelegy-ellipta-ni

    R. Matthews RAPS
    16 Sep 2020
    Share Share
    GSK books 19% sales growth for first quarter
    GSK books 19% sales growth for first quarter

    http://www.pharmatimes.com/news/gsk_books_19_sales_growth_for_first_quarter_1339304

    Selina McKee PHARMATIMES
    29 Apr 2020
    Share Share
    GSK filing accepted by European Medicines Agency for Trelegy Ellipta
    GSK filing accepted by European Medicines Agency for Trelegy Ellipta

    https://www.gsk.com/en-gb/media/press-releases/gsk-filing-accepted-by-european-medicines-agency-for-trelegy-ellipta-use-in-adult-patients-with-asthma/

    PRESS RELEASE
    27 Feb 2020
    Share Share
    GSK Submits Filing to FDA for Trelegy Ellipta Use in Patients With Asthma
    GSK Submits Filing to FDA for Trelegy Ellipta Use in Patients With Asthma

    https://www.businesswire.com/news/home/20191002005525/en

    BUSINESSWIRE
    03 Oct 2019
    Share Share
    AstraZeneca respiratory business gets boost from 3-drug inhaler results
    AstraZeneca respiratory business gets boost from 3-drug inhaler results

    https://www.reuters.com/article/us-astrazeneca-fasenra/astrazeneca-respiratory-business-gets-boost-from-3-drug-inhaler-results-idUSKCN1VI0KB

    Ludwig Burger REUTERS
    29 Aug 2019
    Share Share
    AstraZeneca’s COPD triplet Breztri nabs first nod from Japan
    AstraZeneca’s COPD triplet Breztri nabs first nod from Japan

    https://www.fiercepharma.com/pharma/astrazeneca-s-copd-triplet-breztri-rival-to-gsk-s-trelegy-nabs-first-nod-from-japan

    Angus Liu FIERCE PHARMA
    20 Jun 2019
    Share Share
    FDA draft lays out submission paths for combo products
    FDA draft lays out submission paths for combo products

    https://www.medtechdive.com/news/fda-draft-lays-out-submission-paths-for-combo-products/547807/

    David Lim MEDTECH DRIVE
    07 Feb 2019
    Share Share
    EU expands label of GSK/Innoviva’s COPD inhaler
    EU expands label of GSK/Innoviva’s COPD inhaler

    http://www.pharmatimes.com/news/eu_expands_label_of_gskinnovivas_copd_inhaler_1259755

    Selina McKee PHARMA TIMES
    12 Nov 2018
    Share Share
    Theravance Biopharma Expanded COPD Indication for Trelegy Ellipta in Europe
    Theravance Biopharma Expanded COPD Indication for Trelegy Ellipta in Europe

    https://www.prnewswire.com/news-releases/theravance-biopharma-highlights-expanded-copd-indication-for-trelegy-ellipta-in-europe-300748103.html

    PR NEWSWIRE
    12 Nov 2018
    Share Share
    Vectura and Hikma to jointly develop generic versions of GSK’s Ellipta
    Vectura and Hikma to jointly develop generic versions of GSK’s Ellipta

    https://www.pharmaceutical-technology.com/news/vectura-hikma-ellipta-generic-versions/

    PHARMACEUTICAL TECH
    10 Nov 2018
    Share Share
    GlaxoSmithKline's Shingrix zooms toward blockbuster status despite tight supply
    GlaxoSmithKline's Shingrix zooms toward blockbuster status despite tight supply

    https://www.fiercepharma.com/pharma/despite-tight-supply-gsk-s-shingrix-zooms-to-blockbuster-status

    Eric Sagonowsky FIERCE PHARMA
    31 Oct 2018
    Share Share
    GlaxoSmithKline expands API production for COPD inhalers
    GlaxoSmithKline expands API production for COPD inhalers

    https://www.fiercepharma.com/manufacturing/glaxosmithkline-opens-expanded-api-production-for-copd-inhalers

    Angius Liu FIERCE PHARMA
    24 Oct 2018
    Share Share
    AZ rival to GSK’s COPD drug Anoro fails head-to-head test
    AZ rival to GSK’s COPD drug Anoro fails head-to-head test

    http://www.pmlive.com/pharma_news/az_rival_to_gsks_copd_drug_anoro_fails_head-to-head_test_1249945

    Phil Taylor PMLIVE
    24 Aug 2018
    Share Share
    Hit by surprise setback, AZ explains why inhaler beaten by GSK rival
    Hit by surprise setback, AZ explains why inhaler beaten by GSK rival

    https://endpts.com/hit-by-surprise-setback-astrazeneca-scrambles-to-explain-why-its-two-in-one-copd-inhaler-fails-to-beat-gsk-rival/

    Amber Tong ENDPTS
    23 Aug 2018
    Share Share
    GlaxoSmithKline is plotting a $525M cost-cutting drive instead of Spin-off
    GlaxoSmithKline is plotting a $525M cost-cutting drive instead of Spin-off

    https://www.fiercepharma.com/pharma/gsk-trots-out-cost-cutting-drive-not-consumer-spin-q2-beats

    Carly Helfand FIERCE PHARMA
    26 Jul 2018
    Share Share
    GSK submits regulatory application in Japan for once-daily single inhaler
    GSK submits regulatory application in Japan for once-daily single inhaler

    https://www.gsk.com/en-gb/media/press-releases/gsk-submits-regulatory-application-in-japan-for-once-daily-single-inhaler-triple-therapy-ffumecvi-for-patients-with-copd/

    PRESS RELEASE
    29 May 2018
    Share Share
    Once-Daily Trelegy Ellipta Gains Expanded Indication in the US for the Treatment
    Once-Daily Trelegy Ellipta Gains Expanded Indication in the US for the Treatment

    http://investor.inva.com/news-releases/news-release-details/once-daily-trelegy-ellipta-gains-expanded-indication-us

    PRESS RELEASE
    24 Apr 2018
    Share Share
    EU expands scope of GSK/Innoviva’s asthma inhaler
    EU expands scope of GSK/Innoviva’s asthma inhaler

    http://www.pharmatimes.com/news/eu_expands_scope_of_gskinnovivas_asthma_inhaler_1226718

    Selina McKee PHARMA TIMES
    10 Mar 2018
    Share Share
    GlaxoSmithKline's Elebrato Ellipta (fluticasone furoate / umeclidinium / vilanterol) Receives Approval In Europe
    GlaxoSmithKline's Elebrato Ellipta (fluticasone furoate / umeclidinium / vilanterol) Receives Approval In Europe

    https://www.pharmacompass.com/pdf/news/glaxosmithklines-elebrato-ellipta-lfluticasone-furoate-umeclidinium-vilanterol-receives-approval-in-europe-1517032320.pdf

    EMA
    27 Jan 2018
    Share Share
    GSK’s Anoro Ellipta beats BI’s Spiolto Respimat in COPD trial
    GSK’s Anoro Ellipta beats BI’s Spiolto Respimat in COPD trial

    http://www.pharmatimes.com/news/gsks_anoro_ellipta_beats_bis_spiolto_respimat_in_copd_trial_1210339

    Selina McKee PHARMA TIMES
    02 Nov 2017
    Share Share
    CHMP backs 13 treatments for EU approval
    CHMP backs 13 treatments for EU approval

    http://www.pharmatimes.com/news/chmp_backs_13_treatments_for_eu_approval_1205544

    Selina McKee PHARMA TIMES
    18 Sep 2017
    Share Share
    GSK closes in on EU approval for triple COPD therapy
    GSK closes in on EU approval for triple COPD therapy

    http://www.pmlive.com/pharma_news/gsk_closes_in_on_eu_approval_for_triple_copd_therapy_1205641

    PMLIVE
    18 Sep 2017
    Share Share
    EMA committee recommends approval of once-daily single inhaler triple therapy
    EMA committee recommends approval of once-daily single inhaler triple therapy

    http://www.pharmabiz.com/NewsDetails.aspx?aid=104293&sid=2

    PHARMABIZ
    15 Sep 2017
    Share Share
    GSK's three-in-one inhaler gets positive opinion from EU agency
    GSK's three-in-one inhaler gets positive opinion from EU agency

    http://www.reuters.com/article/us-gsk-copd-approval/gsks-three-in-one-inhaler-gets-positive-opinion-from-eu-agency-idUSKCN1BQ0M0

    Arathy S Nair REUTERS
    15 Sep 2017
    Share Share
    GSK’s inhaler improves asthma control in ‘real world’ study
    GSK’s inhaler improves asthma control in ‘real world’ study

    http://www.pharmatimes.com/news/gsks_inhaler_improves_asthma_control_in_real_world_study_1192433

    Selina McKee PHARMA TIMES
    09 May 2017
    Share Share
    GSK begins phIII study of once-daily closed triple combo therapy FF/UMEC/VI
    GSK begins phIII study of once-daily closed triple combo therapy FF/UMEC/VI

    http://www.pharmabiz.com/NewsDetails.aspx?aid=99308&sid=2

    PHARMABIZ
    19 Dec 2016
    Share Share
    GSK files triple combo for COPD in Europe
    GSK files triple combo for COPD in Europe

    http://www.pharmatimes.com/news/gsk_files_triple_combo_for_copd_in_europe_1180010

    Selina McKee PHARMATIMES
    05 Dec 2016
    Share Share
    Relvar Ellipta receives Japanese approval to treat patients with COPD
    Relvar Ellipta receives Japanese approval to treat patients with COPD

    http://www.pharmabiz.com/NewsDetails.aspx?aid=99048&sid=2

    PHARMABIZ
    05 Dec 2016
    Share Share
    Mereo BioPharma appoints CFO
    Mereo BioPharma appoints CFO

    http://www.pmlive.com/pharma_appointments/mereo_biopharma_appoints_cfo_1177604

    PMLIVE
    21 Nov 2016
    Share Share
    What Puts a New Drug Launch in Line for Victory? Ask Gilead, Biogen and J&J
    What Puts a New Drug Launch in Line for Victory? Ask Gilead, Biogen and J&J

    http://www.fiercepharma.com/pharma/specialty-drugs-big-price-tags-top-market-performance-report-finds

    Eric Sagonowsky FIERCE PHARMA
    18 Nov 2016
    Share Share
    Propeller Health gets USFDA marketing nod for Propeller platform
    Propeller Health gets USFDA marketing nod for Propeller platform

    http://www.pharmabiz.com/NewsDetails.aspx?aid=98577&sid=2

    PHARMABIZ
    10 Nov 2016
    Share Share
    GSK's Bexsero Vaccine Growing Fast, Despite
    GSK's Bexsero Vaccine Growing Fast, Despite "Tight" Supply

    http://www.pmlive.com/pharma_news/gsks_bexsero_vaccine_growing_fast,_despite_tight_supply_1174879

    Phil Taylor PMLIVE
    28 Oct 2016
    Share Share
    GSK's triple COPD therapy tops Symbicort in phase III trial
    GSK's triple COPD therapy tops Symbicort in phase III trial

    http://www.pmlive.com/pharma_news/gsks_triple_copd_therapy_tops_symbicort_in_phase_iii_trial_1044758

    Phil Taylor PMLIVE
    21 Jun 2016
    Share Share
    How Will GlaxoSmithKline's Triple Therapy Combination Perform In The Market?
    How Will GlaxoSmithKline's Triple Therapy Combination Perform In The Market?

    www.seekingalpha.com/article/3839766-will-glaxosmithklines-triple-therapy-combination-perform-market

    SEEKING ALPHA
    27 Jan 2016
    Share Share
    Anvisa approves novel medicines for kidney cancer and lung disease
    Anvisa approves novel medicines for kidney cancer and lung disease

    http://portal.anvisa.gov.br/wps/content/anvisa+portal/anvisa/sala+de+imprensa/menu+-+noticias+anos/2015/anvisa+aprova+medicamentos+ineditos+para+cancer+renal+e+doenca+pulmonar

    ANVISA
    16 Dec 2015
    Share Share
    Prescription for Glaxo: A New Boss?
    Prescription for Glaxo: A New Boss?

    http://www.bloomberg.com/news/articles/2015-05-05/prescription-for-glaxo-a-new-boss-

    Oliver Staley BLOOMBERG BUSINESS
    05 May 2015
    Share Share
    Gsk's BREO® ELLIPTA® (Fluticasone Furoate/Vilanterol) Approved in US For Asthma
    Gsk's BREO® ELLIPTA® (Fluticasone Furoate/Vilanterol) Approved in US For Asthma

    http://www.gsk.com/en-gb/media/press-releases/2015/fda-approves-breo-ellipta-for-the-treatment-of-adults-with-asthma-in-the-us/

    Press Release GSK
    01 May 2015
    Share Share
    GSK's Breo For Asthma? FDA Panel Says Yes--But Only In Adults
    GSK's Breo For Asthma? FDA Panel Says Yes--But Only In Adults

    http://www.fiercepharma.com/story/gsks-breo-asthma-fda-panel-says-yes-only-adults/2015-03-19

    Carly Helfand FIERCE PHARMA
    20 Mar 2015
    Share Share
    FDA Staff Finds No New Safety Problems With Glaxo's Asthma Drug
    FDA Staff Finds No New Safety Problems With Glaxo's Asthma Drug

    http://in.reuters.com/article/2015/03/17/us-glaxosmithkline-fda-idINKBN0MD1KY20150317

    Vidya L Nathan And Amrutha Penumudi REUTERS
    17 Mar 2015
    Share Share
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    Inke Vilanterol Trifenatate

    Access Virtual Booth

    Contact Supplier

    View Presentation

    veranova-m-2024-04-22

    Access Virtual Booth

    Contact Supplier

    View Presentation

    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search